AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) has announced the pricing of a $8.0 million public offering. The offering consists of 2,000,000 shares of common stock (or pre-funded warrants), along with Class E and Class F warrants, priced at $4.00 per share.
The offering includes Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with a $4.00 exercise price. Maxim Group LLC is serving as the sole placement agent, with the offering expected to close around July 30, 2025.
Positive
- Expected to raise $8.0 million in gross proceeds to strengthen balance sheet
- Warrants provide potential for additional future capital through exercise
Negative
- Potential dilution for existing shareholders
- Offering price represents significant share capital increase
News Market Reaction – AIM
On the day this news was published, AIM declined 56.25%, reflecting a significant negative market reaction. Argus tracked a trough of -42.2% from its starting point during tracking. Our momentum scanner triggered 53 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $5.50M at that time. Trading volume was exceptionally heavy at 11.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
OCALA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the pricing of a public offering of an aggregate of 2,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class E warrants to purchase up to 2,000,000 shares of common stock, and Class F warrants to purchase up to 2,000,000 shares of common stock, at a combined public offering price of
Maxim Group LLC is acting as sole placement agent in connection with this offering.
The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-284443) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the "SEC") on July 28, 2025. The offering is being made only by means of a prospectus which is a part of the effective Registration Statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to this offering, when available, will be filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in the Registration Statement, the Company’s most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
FAQ
What is the size and price of AIM ImmunoTech's (AIM) public offering?
When will AIM ImmunoTech's (AIM) public offering close?
What are the terms of AIM ImmunoTech's (AIM) warrants in the offering?
Who is the placement agent for AIM ImmunoTech's (AIM) public offering?
How can investors access the prospectus for AIM ImmunoTech's (AIM) offering?
